美迪西請回答為您講解GLP-1 受體激動(dòng)劑的發(fā)展。

胰高血糖素樣肽-1（GLP-1）受體激動(dòng)劑布局最多的適應(yīng)癥為2型糖尿病和肥胖癥。

GLP-1 receptor agonists are now used for the treatment of type 2 diabetes and obesity.

回顧從前，從發(fā)現(xiàn)GLP-1是胰高血糖素原經(jīng)酶促裂解后產(chǎn)生的，再到Exendent-4 的發(fā)現(xiàn)。

Looking back, GLP-1 was found to be a cleavage product of proglucagon processing.

Exendent-4 是GLP-1發(fā)展史上的一個(gè)關(guān)鍵的突破。Exendent-4是一種對GLP-1受體具有激動(dòng)作用但能抵抗DPP-4降解的肽。司美格魯肽是全球首款口服的GLP-1受體激動(dòng)劑。

A key breakthrough came from the discovery of exendent-4. Exendent-4 is a peptide with agonistic properties at the GLP-1 receptor but resistance to degradation by DPP-4.Semiglutide, the first oral GLP-1 receptor agonist marked the next milestone.

美迪西“GLP-1”新藥研發(fā)服務(wù)平臺

美迪西內(nèi)分泌及代謝性疾病模型